TLR8: No gain, no pain

TLRs have been well characterized in the context of immunity, although TLR8 is understudied due to its controversial function in mice. In this issue of JEM, the new work by Zhang et al. (https://doi.org/10.1084/jem.20180800) demonstrates that TLR8 activated by miR-21 controls neuropathic pain using...

Descripción completa

Detalles Bibliográficos
Autor principal: Barrat, Franck J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2018
Materias:
News
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279395/
https://www.ncbi.nlm.nih.gov/pubmed/30455266
http://dx.doi.org/10.1084/jem.20181899
_version_ 1783378497831436288
author Barrat, Franck J.
author_facet Barrat, Franck J.
author_sort Barrat, Franck J.
collection PubMed
description TLRs have been well characterized in the context of immunity, although TLR8 is understudied due to its controversial function in mice. In this issue of JEM, the new work by Zhang et al. (https://doi.org/10.1084/jem.20180800) demonstrates that TLR8 activated by miR-21 controls neuropathic pain using a non-MyD88–dependent pathway.
format Online
Article
Text
id pubmed-6279395
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-62793952019-06-03 TLR8: No gain, no pain Barrat, Franck J. J Exp Med News TLRs have been well characterized in the context of immunity, although TLR8 is understudied due to its controversial function in mice. In this issue of JEM, the new work by Zhang et al. (https://doi.org/10.1084/jem.20180800) demonstrates that TLR8 activated by miR-21 controls neuropathic pain using a non-MyD88–dependent pathway. Rockefeller University Press 2018-12-03 /pmc/articles/PMC6279395/ /pubmed/30455266 http://dx.doi.org/10.1084/jem.20181899 Text en © 2018 Barrat http://www.rupress.org/terms/https://creativecommons.org/licenses/by-nc-sa/4.0/This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle News
Barrat, Franck J.
TLR8: No gain, no pain
title TLR8: No gain, no pain
title_full TLR8: No gain, no pain
title_fullStr TLR8: No gain, no pain
title_full_unstemmed TLR8: No gain, no pain
title_short TLR8: No gain, no pain
title_sort tlr8: no gain, no pain
topic News
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279395/
https://www.ncbi.nlm.nih.gov/pubmed/30455266
http://dx.doi.org/10.1084/jem.20181899
work_keys_str_mv AT barratfranckj tlr8nogainnopain

Ejemplares similares